bryostatin-1

Bryostatin‑1 is a naturally occurring, macrocyclic lactone derived from the marine organism Bugula neritina. It is a small molecule that acts as a potent modulator and activator of protein kinase C (PKC) enzymes, which are involved in regulating cell proliferation, differentiation, apoptosis, and synaptic function. Bryostatin‑1 has been investigated for its potential therapeutic effects in Alzheimer's disease (AD), multiple sclerosis (MS), various cancers, HIV infection, stroke, and other neurological disorders. Its mechanism involves activation of PKC isozymes leading to downstream effects on neuronal survival and synaptic plasticity; it also exhibits anti-inflammatory properties by modulating immune cell phenotypes[3][4][5][6][8]. Clinical trials have shown mixed results in AD but suggest possible benefit in specific patient subgroups or when used as part of combination therapy[3][4][8]. The drug remains investigational with ongoing development primarily by Synaptogenix.

Other names

BRYOCHEBI:8835383314-01-6